Maternal healthcare technology company secures capital to enter the consumer segment. Also participating in the pre-series A round are the tal64 syndicate and more.
Janitri, a pioneering maternal healthcare technology company, has Successfully raised $1.4 million in a pre-Series A round led by ace investor Ashish Kacholia, who has doubled down on the company, having also participated in the previous round.
Participants in this round included Prateek Maheshwari, Pradip Todi via O2 Angels, and the tal64 syndicate.
Arun Agarwal (left) with Ashish Kacholia.
Ashish commented:
“Arun has spent time and effort in understanding unmet customer needs in the 1000-days journey of maternal care.”
“Janitri’s product is compact, full function, and enables cost-effective monitoring of mother and newborn for both hospital and home segment.”
“It is a large market in India and overseas and hopefully, Janitri will identify more such market gaps to build a large and profitable medtech company out of India”
About Janitri
Founded in 2016 by Arun Agarwal, Janitri is revolutionizing maternal and child healthcare through innovative medical devices and technology solutions.
Founder and CEO Arun Agarwal says:
“Janitri is building products focused on the 1000-day pregnancy journey of a mother and child.”
“The goal is to bring joy to the mother, father, and the whole family as they anticipate and prepare for the arrival of their newborn into the world.”
The company's flagship product, Keyar, is an intrapartum monitoring device that tracks vital signs of pregnant women during labor, helping detect complications early and enabling timely interventions.
Janitri addresses a critical gap in healthcare delivery — inadequate vital signs monitoring during labor, which contributes significantly to maternal and child mortality rates.
Their affordable, simple, and medical-grade monitors provide an accessible solution for birthing centers across India and emerging markets.
Business Growth and Impact
The company has demonstrated impressive growth, achieving ₹8.5 crores in revenue for FY 2024-25, representing a more than 2x increase from the previous fiscal year.
Notably, Arun highlighted that the order book for Q1 FY26 is already 2x of Q1 FY25.
Currently, Janitri's devices have monitored the vital signs of over 200,000 pregnant women each month across 800+ hospitals throughout India and 10 more countries.
The company estimates a ₹2,000 crore market opportunity in India alone, with over 200,000 hospitals that could benefit from its solutions.
Entry into the Consumer Segment
While the current funding round is primarily based on Janitri's proven B2B success, a portion of the raised funds will be strategically allocated to enter the consumer segment.
Janitr’s offerings for the consumer segment across the 1000-day pregnancy journey.
This represents a significant evolution in the company's approach, extending its mission beyond hospital settings to directly serve families during the critical 1000-day journey.
With this new funding, Janitri plans to:
Expand its sales and support network across India
Enhance its product suite with new offerings focused on in-home maternal healthcare
Develop wearable vital signs patches for remote monitoring in the third trimester
Create neonatal monitoring solutions for high-risk newborns
Scale operations to reach ₹3 crore monthly revenue in the next 12 months
Janitri is focused on inventing at-home maternal healthcare with its products.
Furthermore, the consumer-focused expansion aligns with their refreshed positioning of bringing joy to mothers, fathers, and entire families as they anticipate and prepare for their newborn's arrival, making quality maternal care accessible at every touchpoint of the pregnancy journey.
Founder Arun Agarwal commented:
“Each time I hear a story of how our device helped detect a complication early and enabled timely intervention, it gives me goosebumps. This is why we do what we do.”
“The fact that we can quantify our impact, and see it grow with every passing month, is what keeps us going.”
